# Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

> **NCT07179939** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 288 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Trastuzumab rezetecan
- **DRUG:** Pyrotinib
- **DRUG:** Dalpiciclib
- **DRUG:** Trastuzumab
- **DRUG:** ET: Letrozole/ Anastrozole/ Exemestane/ Fulvestrant/ Leuprorelin/ Goserelin.

## Key facts

- **NCT ID:** NCT07179939
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2030-12-30
- **Final completion:** 2031-12-30
- **Target enrollment:** 288 (ESTIMATED)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07179939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07179939, "Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT07179939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*